92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER
Morton's Neuroma
Brown UniversitymixtureN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Morton's Neuroma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cntx-4975 Centrexion Therapeutics | Phase 2 | B |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE National Institutes of Health Clinical Center (CC) | Phase 1 | CC |
Lopain National Institutes of Health Clinical Center (CC) | Phase 1 | CC |
Capsaicin Centrexion Therapeutics | Phase 1 | CC |
Xylocaine AstraZeneca | Early Phase 1 | CC |
Same molecule, other indications
92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →